Titan Pharmaceuticals (NSDQ:TTNP) and Braeburn Pharmaceuticals said today that they plan to end a 2012 licensing agreement that gave Braeburn exclusive rights to commercialize Probuphine in the U.S. and Canada.
Probuphine, which was developed using Titan’s ProNeura continuous drug-delivery tech, is an implant that can be placed in a patient’s upper arm in an outpatient office procedure. The FDA approved Probuphine in May 2016 to deliver buprenorphine as a long-term maintenance treatment for people suffering from opioid addiction.
Get the full story at our sister site, Drug Delivery Business News.
The post Titan, Braeburn end commercialization deal for Probuphine drug-delivery implant appeared first on MassDevice.
from MassDevice https://ift.tt/2xBrp5F
Cap comentari:
Publica un comentari a l'entrada